NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

IndexRUT P/E- EPS (ttm)-2.71 Insider Own4.35% Shs Outstand54.50M Perf Week2.34%
Market Cap379.40M Forward P/E5.59 EPS next Y1.25 Insider Trans0.30% Shs Float51.92M Perf Month9.05%
Enterprise Value899.30M PEG- EPS next Q-0.10 Inst Own66.84% Short Float15.39% Perf Quarter35.20%
Income-131.60M P/S0.39 EPS this Y469.57% Inst Trans4.30% Short Ratio6.26 Perf Half Y-24.43%
Sales965.40M P/B0.69 EPS next Y47.06% ROA-8.15% Short Interest7.99M Perf YTD-26.88%
Book/sh10.14 P/C2.48 EPS next 5Y- ROE-21.63% 52W High15.10 -53.71% Perf Year-0.99%
Cash/sh2.82 P/FCF4.02 EPS past 3/5Y- - ROIC-10.76% 52W Low4.02 73.88% Perf 3Y-77.63%
Dividend Est.- EV/EBITDA15.27 Sales past 3/5Y-16.20% -1.15% Gross Margin29.20% Volatility7.98% 6.06% Perf 5Y-90.71%
Dividend TTM- EV/Sales0.93 EPS Y/Y TTM76.88% Oper. Margin-5.14% ATR (14)0.41 Perf 10Y-77.51%
Dividend Ex-Date- Quick Ratio3.51 Sales Y/Y TTM-18.56% Profit Margin-13.63% RSI (14)59.80 Recom2.33
Dividend Gr. 3/5Y- - Current Ratio6.32 EPS Q/Q588.34% SMA206.96% Beta1.98 Target Price13.50
Payout- Debt/Eq1.22 Sales Q/Q-26.03% SMA5014.04% Rel Volume0.72 Prev Close7.11
Employees900 LT Debt/Eq1.21 EarningsMay 07 AMC SMA200-8.94% Avg Volume1.28M Price6.99
IPONov 15, 2006 Option/ShortYes / Yes EPS/Sales Surpr.61.36% 1.46% Trades Volume917,327 Change-1.69%
Date Action Analyst Rating Change Price Target Change
Dec-30-24Initiated H.C. Wainwright Buy $15
Aug-22-24Initiated Rodman & Renshaw Buy $16
Mar-07-24Upgrade The Benchmark Company Hold → Buy $5
Nov-20-23Resumed JP Morgan Underweight
Aug-29-23Downgrade The Benchmark Company Buy → Hold
Apr-10-23Upgrade The Benchmark Company Hold → Buy $22
Mar-17-23Downgrade JP Morgan Neutral → Underweight $23 → $9
Nov-10-22Downgrade The Benchmark Company Buy → Hold
Apr-29-22Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-20-22Upgrade The Benchmark Company Hold → Buy $77
Jul-02-25 04:05PM
Jun-23-25 08:05AM
Jun-20-25 08:13AM
Jun-05-25 07:00AM
May-29-25 09:55AM
09:43AM Loading…
May-19-25 09:43AM
May-16-25 10:52AM
May-14-25 07:32AM
May-08-25 09:53AM
03:33AM
May-07-25 10:03PM
10:01PM
05:35PM
04:32PM
04:05PM
05:07PM Loading…
May-01-25 05:07PM
Apr-22-25 08:00AM
Apr-10-25 09:52AM
Apr-09-25 08:45AM
Apr-08-25 12:24AM
Mar-31-25 08:00AM
Mar-26-25 10:32AM
Mar-20-25 04:30PM
08:30AM
08:06AM
Mar-19-25 05:01PM
04:30PM
Mar-18-25 08:00AM
Mar-13-25 11:00AM
08:29AM
08:00AM Loading…
Mar-12-25 08:00AM
Mar-10-25 09:14AM
Mar-04-25 06:59AM
02:45AM
02:05AM
Mar-03-25 05:40PM
04:45PM
04:23PM
Feb-18-25 08:55AM
Feb-07-25 08:06AM
Jan-23-25 09:01AM
Jan-16-25 08:00AM
Jan-14-25 07:30AM
Jan-13-25 09:27AM
Jan-08-25 07:45AM
07:30AM
Dec-30-24 05:26PM
Dec-16-24 08:00AM
Dec-03-24 06:47PM
Nov-08-24 10:04AM
Nov-07-24 02:06PM
01:15AM
Nov-06-24 06:20PM
05:17PM
04:49PM
04:05PM
Nov-04-24 07:30AM
Oct-23-24 07:30AM
Oct-11-24 12:33PM
Oct-09-24 05:09PM
11:09AM
Oct-08-24 05:32PM
Oct-02-24 07:30AM
Sep-26-24 08:05AM
Sep-25-24 07:07AM
Sep-13-24 06:45AM
Sep-12-24 08:30AM
01:27AM
Sep-04-24 05:51PM
08:00AM
Sep-03-24 07:08AM
Aug-30-24 09:55AM
08:33AM
08:33AM
08:16AM
04:32AM
Aug-29-24 06:53PM
Aug-21-24 11:14AM
Aug-20-24 12:03PM
11:30AM
Aug-19-24 05:16PM
05:10PM
Aug-16-24 04:14PM
12:51PM
09:52AM
Aug-07-24 02:45AM
Aug-06-24 05:14PM
05:01PM
08:00AM
Jul-31-24 09:06AM
08:53AM
Jul-25-24 01:20PM
Jul-24-24 07:30AM
Jul-23-24 08:27AM
Jul-22-24 08:00AM
Jul-09-24 07:30AM
Jul-03-24 10:13AM
Jul-02-24 09:43AM
08:13AM
Jun-24-24 06:35AM
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Katkin KeithDirectorMay 23 '25Sale6.307,84449,41786,431May 28 04:08 PM
KEITH KATKINDirectorMay 23 '25Proposed Sale6.307,84449,409May 23 04:04 PM
PAPA JOSEPH CPresident and CEOMay 13 '25Buy5.8360,000349,800342,500May 15 04:02 PM
Fowler Neal FranklinDirectorMar 12 '25Sale5.8335,000204,050101,100Mar 12 06:13 PM
Zoon Kathryn CDirectorMar 12 '25Sale5.7310,00057,30044,482Mar 12 06:13 PM
Fowler Neal FranklinDirectorMar 12 '25Proposed Sale5.8335,000204,005Mar 12 05:34 PM
Zoon Kathryn CDirectorMar 12 '25Proposed Sale5.7310,00057,300Mar 12 05:23 PM
DeGolyer Donald WDirectorNov 12 '24Sale10.9125,000272,750111,100Nov 14 04:18 PM
White Marvin LDirectorNov 11 '24Sale11.9714,287171,01554,092Nov 13 04:04 PM
DeGolyer Donald WDirectorNov 12 '24Proposed Sale11.7725,000294,250Nov 12 05:16 PM
White Marvin LDirectorNov 11 '24Proposed Sale11.7714,287168,158Nov 12 10:34 AM
Last Close
Jul 03 04:00PM ET
3.04
Dollar change
0.00
Percentage change
0.00
%
APVO Aptevo Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-1769.09 Insider Own9.95% Shs Outstand3.22M Perf Week-5.88%
Market Cap9.80M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.90M Perf Month-38.89%
Enterprise Value12.08M PEG- EPS next Q- Inst Own8.88% Short Float0.39% Perf Quarter-88.99%
Income-23.70M P/S- EPS this Y- Inst Trans0.62% Short Ratio0.00 Perf Half Y-96.82%
Sales0.00M P/B- EPS next Y- ROA-182.54% Short Interest0.01M Perf YTD-96.47%
Book/sh-20.20 P/C4.58 EPS next 5Y- ROE-1023.93% 52W High485.37 -99.37% Perf Year-98.77%
Cash/sh0.66 P/FCF- EPS past 3/5Y79.32% 80.96% ROIC-803.80% 52W Low2.81 8.19% Perf 3Y-100.00%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.21% 19.93% Perf 5Y-100.00%
Dividend TTM- EV/Sales- EPS Y/Y TTM97.59% Oper. Margin- ATR (14)1.07 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.67 Sales Y/Y TTM- Profit Margin- RSI (14)33.91 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.67 EPS Q/Q98.81% SMA20-21.06% Beta5.63 Target Price420.00
Payout- Debt/Eq- Sales Q/Q- SMA50-51.04% Rel Volume0.05 Prev Close3.04
Employees42 LT Debt/Eq- EarningsMay 15 BMO SMA200-96.35% Avg Volume2.40M Price3.04
IPOJul 20, 2016 Option/ShortNo / Yes EPS/Sales Surpr.-4.28% - Trades Volume130,195 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Jun-21-25 09:00AM
Jun-20-25 11:30AM
08:55AM
Jun-18-25 10:52AM
08:01AM
08:05AM Loading…
Jun-13-25 08:05AM
May-22-25 08:05AM
May-15-25 08:05AM
May-08-25 08:45AM
Apr-22-25 04:05PM
Apr-21-25 02:40PM
Apr-04-25 04:05PM
Apr-03-25 08:50AM
Mar-20-25 02:26PM
08:35AM
08:05AM Loading…
Mar-18-25 08:05AM
Mar-06-25 08:00AM
Feb-15-25 06:59PM
Feb-14-25 08:05AM
Jan-15-25 08:00AM
Dec-12-24 12:50PM
09:00AM
Dec-04-24 08:35AM
Nov-29-24 09:55AM
Nov-26-24 08:35AM
Nov-22-24 08:35AM
Nov-20-24 08:35AM
Nov-11-24 08:15AM
Nov-07-24 08:05AM
Oct-29-24 08:05AM
04:05PM Loading…
Sep-18-24 04:05PM
Sep-16-24 08:05PM
08:20AM
08:05AM
Sep-13-24 08:20AM
08:05AM
Aug-13-24 08:05AM
Aug-08-24 08:05AM
Jul-01-24 04:20PM
Jun-28-24 09:20AM
Jun-17-24 07:40AM
Jun-03-24 08:05AM
May-14-24 08:05AM
May-08-24 12:54PM
08:05AM
May-02-24 07:37AM
Apr-16-24 12:47PM
Apr-15-24 04:05PM
Apr-11-24 08:15AM
08:00AM
Apr-10-24 09:00AM
Mar-18-24 06:00AM
Mar-07-24 08:55AM
Mar-05-24 01:51PM
08:05AM
Mar-04-24 09:00AM
Nov-14-23 08:05AM
Nov-01-23 07:45AM
Aug-10-23 08:05AM
Aug-06-23 07:14AM
Aug-04-23 06:40PM
Aug-01-23 10:15PM
Jul-30-23 02:17PM
Jul-18-23 08:05AM
May-11-23 08:05AM
Apr-01-23 08:51AM
Mar-30-23 07:45AM
07:30AM
Mar-29-23 10:13AM
Mar-03-23 06:57PM
Feb-13-23 08:05AM
Jan-09-23 08:05AM
Dec-12-22 09:54AM
07:35AM
Nov-10-22 08:05AM
Nov-09-22 08:05AM
Nov-03-22 09:06AM
Sep-19-22 08:45AM
Aug-11-22 08:05AM
Jun-09-22 08:05AM
May-12-22 08:05AM
Apr-12-22 08:05AM
Mar-29-22 08:05AM
Mar-24-22 08:05AM
Feb-09-22 08:05AM
Jan-21-22 08:05AM
Dec-15-21 08:05AM
Dec-10-21 05:38PM
Nov-23-21 08:05AM
07:59AM
Nov-15-21 08:05AM
Nov-12-21 08:05AM
Nov-11-21 04:45PM
08:30AM
Nov-02-21 09:00AM
Oct-27-21 08:05AM
Oct-26-21 08:05AM
Sep-28-21 08:05AM
Aug-17-21 08:05AM
Aug-12-21 08:05AM
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.